Design and synthesis of bile acid derivatives and their activity against colon cancer

Zongyuan Wang; Xin Qiang; Yijie Peng; Yanni Wang; Quanyi Zhao; Dian He

doi:10.1039/d2md00220e

Design and synthesis of bile acid derivatives and their activity against colon cancer

RSC Med Chem. 2022 Aug 19;13(11):1391-1409. doi: 10.1039/d2md00220e. eCollection 2022 Nov 16.

Authors

Zongyuan Wang¹, Xin Qiang¹, Yijie Peng¹, Yanni Wang¹, Quanyi Zhao¹, Dian He¹

Affiliation

¹ Materia Medica Development Group, Institute of Medicinal Chemistry, School of Pharmacy of Lanzhou University Lanzhou 730000 China zhaoqy@lzu.edu.cn +869318915686 +869318915686.

Abstract

Bile acids (BAs) containing both hydrophilic hydroxyl and carboxyl groups and hydrophobic methyl and steroid nuclei can promote the absorption of fat and other substances in the intestine, and they are synthesized by cholesterol in the liver and then returned to the liver through enteric liver circulation. Because there are many BA receptors on the cell membrane of colon tissues, BAs can improve the specific delivery and transport of medicines to colon tissues. Moreover, BAs have a certain anticancer and inflammation activity by themselves. Based on this theory, a series of BA derivatives against colon cancer including cholic acid (CA), chenodeoxycholic acid (CDCA), ursodeoxycholic acid (UDCA) and lithocholic acid (LCA) were designed and synthesized, and their antitumor activity was evaluated. For in vitro anti-tumor tests, all the compounds displayed cell proliferative inhibition to nine human malignant tumor cell lines to some degree, and in particular they showed stronger inhibition to the colon cancer cells than the other cell lines. Among them, four compounds (4, 5, 6, and 7) showed stronger activity than the other compounds as well as the positive control 5-FU against HCT116 cells, and their IC₅₀ was between 21.32 μmol L^-1 and 28.90 μmol L^-1; cell clone formation and migration tests showed that they not only effectively inhibited the formation of HCT116 cell colonies, but also inhibited the HCT116 cell migration and invasion; moreover, they induced apoptosis, arrested the mitotic process at the G2/M phase of the cell cycle, reduced the mitochondrial membrane potential, increased the intracellular ROS levels, and reduced the expression of Bcl-2 and p-STAT3 in HCT 116 cells. In addition, they also displayed intermediate anti-inflammatory activity by inhibiting inflammatory mediators NO and downregulating TNF-α expression, which also is one of the causes of colon cancer. This suggests that they deserve to be further investigated as candidates for colon cancer treatment drugs.